Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESUS C FABREGAS MERCADO

Allopathic & Osteopathic Physicians Internal Medicine Hematology

NPI
1467681833
CMS profile
339306
Location
HALLANDALE BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$11.92

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
Gilead Sciences, Inc. $11.92 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESUS C FABREGAS MERCADO

NPI 1467681833 · CMS profile ID 339306

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology

HALLANDALE BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467681833?year=2021&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESUS C FABREGAS MERCADO, NPI 1467681833, CMS profile ID 339306. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467681833?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JESUS C FABREGAS MERCADO, NPI 1467681833, CMS profile ID 339306. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467681833?year=2021&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JESUS C FABREGAS MERCADO, NPI 1467681833, CMS profile ID 339306, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1467681833?year=2021&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.92 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $11.9206/01/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845872825 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $11.92 1
PY2022 $154.81 2
PY2023 $3,371.18 6
PY2024 $14,199.23 15
PY2025 $628.77 8

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $114,690.91 4
PY2022 Principal investigator $12,000.00 1
PY2021 Principal investigator $27,244.24 4
PY2020 Principal investigator $134,333.86 28
PY2019 Principal investigator $126,806.94 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

28 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 F. Hoffmann-La Roche AG $5,544.00 12/17/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 742993701
Principal investigator 1 F. Hoffmann-La Roche AG $7,394.79 12/15/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
1L NSCLC DX ALL COMER SQUAMOUS No dispute reported 06/30/2026 742993661
Principal investigator 1 Genentech, Inc. $143.60 11/20/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER No dispute reported 06/30/2026 742993755
Principal investigator 1 F. Hoffmann-La Roche AG $2,499.75 11/10/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 742993693
Principal investigator 1 Merck Sharp & Dohme Corporation $150.00 11/05/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na ve, metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 No dispute reported 06/30/2026 740812265
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 10/15/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in combination with lenvatinib E7080,MK-7902 versus docetaxel in previously treated participants with metastatic non-small cell lung cancer NSCLC and progressive disease PD after platinum doublet chemotherapy and immunotherapy anti-PD-1,PD-L1 inhibitor LEAP-008 No dispute reported 06/30/2026 740812263
Principal investigator 1 Genentech, Inc. $11,499.16 10/06/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER No dispute reported 06/30/2026 742993746
Principal investigator 1 Merck Sharp & Dohme Corporation $922.98 09/15/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in combination with lenvatinib E7080,MK-7902 versus docetaxel in previously treated participants with metastatic non-small cell lung cancer NSCLC and progressive disease PD after platinum doublet chemotherapy and immunotherapy anti-PD-1,PD-L1 inhibitor LEAP-008 No dispute reported 06/30/2026 740773415
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 09/15/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in combination with lenvatinib E7080,MK-7902 versus docetaxel in previously treated participants with metastatic non-small cell lung cancer NSCLC and progressive disease PD after platinum doublet chemotherapy and immunotherapy anti-PD-1,PD-L1 inhibitor LEAP-008 No dispute reported 06/30/2026 740773419
Principal investigator 1 Merck Sharp & Dohme Corporation $752.98 09/15/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in combination with lenvatinib E7080,MK-7902 versus docetaxel in previously treated participants with metastatic non-small cell lung cancer NSCLC and progressive disease PD after platinum doublet chemotherapy and immunotherapy anti-PD-1,PD-L1 inhibitor LEAP-008 No dispute reported 06/30/2026 740773421
Principal investigator 1 Merck Sharp & Dohme Corporation $177.75 08/27/2020 Non-covered Recipient Entity
BILLINGS CLINIC CANCER CENTER
A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na ve, metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 No dispute reported 06/30/2026 740845135
Principal investigator 1 F. Hoffmann-La Roche AG $6,930.00 08/18/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 742993687
Principal investigator 1 Merck Sharp & Dohme Corporation $1,500.00 08/11/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na ve, metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 No dispute reported 06/30/2026 740812261
Principal investigator 1 United Therapeutics Corporation $950.28 06/12/2020 Covered Recipient Teaching Hospital
Billings Clinic
A TWO-PART OPEN-LABEL RANDOMIZED PHASE II/III STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER No dispute reported 06/30/2026 752564049
Principal investigator 1 Genentech, Inc. $18,797.50 06/01/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC No dispute reported 06/30/2026 742993710
Principal investigator 1 AstraZeneca Pharmaceuticals LP $2,220.00 05/14/2020 Covered Recipient Teaching Hospital
Billings Clinic
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC) No dispute reported 06/30/2026 736745685
Principal investigator 1 Merck Sharp & Dohme Corporation $26,055.96 05/11/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na ve, metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 No dispute reported 06/30/2026 740762861
Principal investigator 1 Genentech, Inc. $3,189.00 04/28/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER No dispute reported 06/30/2026 742993737
Principal investigator 1 Merck Sharp & Dohme Corporation $529.73 04/27/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in combination with lenvatinib E7080,MK-7902 versus docetaxel in previously treated participants with metastatic non-small cell lung cancer NSCLC and progressive disease PD after platinum doublet chemotherapy and immunotherapy anti-PD-1,PD-L1 inhibitor LEAP-008 No dispute reported 06/30/2026 740773379
Principal investigator 1 Merck Sharp & Dohme Corporation $13,027.98 04/16/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in combination with lenvatinib E7080,MK-7902 versus docetaxel in previously treated participants with metastatic non-small cell lung cancer NSCLC and progressive disease PD after platinum doublet chemotherapy and immunotherapy anti-PD-1,PD-L1 inhibitor LEAP-008 No dispute reported 06/30/2026 740773417
Principal investigator 1 United Therapeutics Corporation $2,760.00 04/08/2020 Covered Recipient Teaching Hospital
Billings Clinic
A TWO-PART OPEN-LABEL RANDOMIZED PHASE II/III STUDY OF DINUTUXIMAB AND IRINOTECAN VERSUS IRINOTECAN FOR SECOND-LINE TREATMENT OF SUBJECTS WITH RELAPSED OR REFRACTORY SMALL CELL LUNG CANCER No dispute reported 06/30/2026 752564009
Principal investigator 1 Merck Sharp & Dohme Corporation $994.40 04/06/2020 Non-covered Recipient Entity
BILLINGS CLINIC CANCER CENTER
A Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treatment-na ve, metastatic non-small cell lung cancer NSCLC who have a tumor proportion score TPS greater than or equal to 1 No dispute reported 06/30/2026 740845315
Principal investigator 1 Genentech, Inc. $172.32 04/02/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER No dispute reported 06/30/2026 742993729
Principal investigator 1 F. Hoffmann-La Roche AG $1,259.70 03/24/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 742993679
Principal investigator 1 Genentech, Inc. $4,120.00 03/12/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
ATEZOLIZUMAB VERSUS PLACEBO AS ADJUVANT THERAPY IN LOCALLY ADVANCED HEAD AND NECK CANCER No dispute reported 06/30/2026 742993723
Principal investigator 1 AbbVie Inc. $500.00 03/10/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
M16-298 No dispute reported 06/30/2026 721139167
Principal investigator 1 F. Hoffmann-La Roche AG $5,544.00 02/06/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
1L NSCLC DX ALL COMER NON SQUAMOUS No dispute reported 06/30/2026 742993671
Principal investigator 1 Merck Sharp & Dohme Corporation $1,170.00 01/16/2020 Covered Recipient Teaching Hospital
BILLINGS CLINIC
A Phase 3, multicenter, randomized, open-label trial to compare the efficacy and safety of pembrolizumab MK-3475 in combination with lenvatinib E7080,MK-7902 versus docetaxel in previously treated participants with metastatic non-small cell lung cancer NSCLC and progressive disease PD after platinum doublet chemotherapy and immunotherapy anti-PD-1,PD-L1 inhibitor LEAP-008 No dispute reported 06/30/2026 740812259